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Abstract
The purpose of this research is to investigate potential strategic variables that executives at small
to mid-sized biopharmaceutical companies should consider during the period of a drug launch.
Bringing a product to market is a critical event for any biopharmaceutical company. It marks a
major turning point within the biopharmaceutical's lifecycle and the company that can
successfully launch a product will be viewed as a different asset class. Therefore, it is critical to
understand potential drivers of the value and to encourage executives to raise probing questions
when they are considering the next round of financing or whether to provide guidance.
This study analyzed forty-six non-generic, therapeutic drugs launched in the US during January
2000- December 2009 by small to mid-sized biopharmaceutical companies with market
capitalizations less than $20 billion at the time of launch. Predictor variables that were initially
considered in the analysis are the following: management providing a sales guidance (binary),
partnership (binary), market size of the partner(s) at the time of launch, specialty/primary care
indication (binary), difference between year two actual sales number and that of pre-launch
estimate, difference between year two actual sales number and that of post-launch estimate,
financing activity prior to launch (binary), financing activity after launch (binary), average pre-
launch file-to-offer discount, average post-launch file-to-offer discount, number of drugs
launched by the same company (control variable) and NBI performance (control variable).
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Multiple linear regression analyses were then performed to determine which of these parameters
were predictive of changes in stock price and changes in market capitalization. Those companies
that did not provide guidance at the time of launch and raised additional capital within two years
after launch performed better than those that did otherwise. Neither a partnership nor the market
size of the partner contributed to either of the outcome measures. Whether or not the product is a
specialty product also did not make any significant contribution to the models.
The results from this study suggest several possible strategic and actionable items that can guide
management to ask the right questions during the period around a drug launch.
Thesis Supervisor: Brian Pereira, MD, MBA
Thesis Supervisor: Jonathan J. Fleming, MPA
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1. Introduction
1.1 Background
Executives at growing biopharmaceutical companies are faced with numerous challenges.
Companies not only have to exquisitely manage the commercialization of their products but also
have to develop a deep enough pipeline. In addition, there are inherent risks that are associated
with commercializing a product, such as uncertainty associated with the reimbursement
landscape and the performance of the product in its therapeutic area, to name a few.
Drug commercialization is one of the most critical events for biopharmaceutical companies. The
drug launch can serve as a significant value inflection point for a company given high investor
interest at this juncture, and is often subject to a high degree of investor speculation. In addition,
launching a drug is costly and often requires the company to seek additional sources of capital to
continue its progress.
Given the importance of a drug launch to a company's life cycle, our research sets out to identify
potential drivers that may play a meaningful role in a successful drug launch and thereby to
encourage the management to ask probing questions as they are about to launch a drug. The
study has found an interesting set of observations from a ten-year period of 46 product launches
by publicly traded small- to mid-sized biopharmaceutical companies.
1.2 Defining the biopharmaceutical industry
There are many definitions of "biopharmaceuticals" not only within the scientific community but
also in other industry sectors and the press (Rader 2005). Classifying companies as
biopharmaceutical can be even more confusing. Some biopharmaceutical companies, such as
Biogen, Amgen and Genzyme, develop, manufacture, and market synthetic drugs. Conversely,
traditional large pharmaceutical companies, including Hoffmann-La Roche and Merck, are also
involved in biopharmaceuticals. Even though the term "biopharmaceutical" (or "biotechnology")
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company usually refers to a firm whose goal is to develop new protein-based molecules, this
study will use the broader definition to include those firms developing any new drug, be it a
biologic or small molecule.
1.2.1 Business dynamics within the sector
Overall, the introduction of biotechnology added complexity to drug development. In the late
1990s and into early 2000, biotechnology matured relatively rapidly as it underwent a boom. The
initial public offering (IPO) served as a reasonable exit option for early stage biotech investors to
achieve a satisfying return on their investments. In addition, public and private investors
provided sources of capital to fund innovation to reach a value inflection point.
Today, the health care industry as a whole is undergoing a major transformation into an
outcomes-driven ecosystem. This shift is driven largely by the need to make the health care
sustainable with its cost outpacing inflation and fiscally constrained budgets. Growing costs are
at odds with legislative efforts to expand access to greater portions of the population, so payers
will inevitably focus more on the cost-effectiveness of a medical intervention. Drug companies
will face increased pressure on prices and demand to prove the comparative effectiveness and
efficiency of their products. Ever changing FDA regulatory requirements increase uncertainty
and risks associated with drug development. All of this points to an extremely challenging
environment where biotechnology companies will need to spend more time and financial
resources on additional data (Ernst & Young 2011).
1.2.2 Drug development and cost
It is costly to discover and develop a new drug due to expensive research processes, costs
associated with clinical trials, regulatory approval procedures and costs associated with
manufacturing. A study by DiMasi et al. estimates the average capitalized cost per approved
biopharmaceutical in 2006 to be approximately $1.24B. In addition, the authors found that this
cost along with the time it takes to bring a new drug to market have increased significantly over
the last 10 years (DiMasi and Grabowski 2007). Not surprisingly such increased cost associated
with R&D has translated to increased need for funding.
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In addition to the high cost associated with drug development, there is an extremely high risk of
failure in biopharmaceutical research and development. According to a recent report from KMR
Group, a biopharmaceutical industry consultancy, the average success rate from preclinical to
clinical studies for biologics was approximately 12% and that of small molecule drugs was about
2%. The biologics success rates for each clinical hurdle are the following: 17% at Phase I, 27%
at Phase 11, 58% at Phase III and 82% at the registration phase. For small molecules the success
was calculated to be 4%, 9%, 44% and 78%, respectively (Philippidis 2012). The Tufts Center
for the Study of Drug Development has shown that when looking beyond success in clinical
studies, large molecules had a clinical approval success rate of 32% whereas small molecules
had a rate of 13% for the period between 1993 and 2004 (Figure 1, DiMasi et al. 2010).
Source: DiMasi et al 2010
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Figure 1 Phase transition probabilities and clinical approval success rates for small and large molecules
Lastly, drug development requires many years. A typical timeframe can take up to 10-15 years
from the discovery of the molecule in a laboratory to its marketing stage (Figure 2). Given that
most patents expire after 20 years, such a long development timeframe for typical
biopharmaceutical molecules would only leave behind a very short window of 5-10 years to
generate market revenue.
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Source: Modified Kaitlin 2010; 15.363 Lecture Fleming J., Zarur A., MIT Sloan School of Management Feb 2010
Figure 2 Typical phases from research to post-market for a drug candidate and integrated R&D roles of major
stakeholders
The relationship between the biopharmaceutical industry and the traditional pharmaceutical
sector is a rather interesting one. Biopharmaceutical companies tend to have limited resources
and may gain access to capital by selling or out-licensing drug candidates or establishing
alliances with pharmaceutical companies. On the other hand, pharmaceutical companies with a
dried out drug pipeline seek out potential drug candidates being developed by the
biopharmaceutical companies to fill their own pipelines.
1.3 The capital base available for the biopharmaceutical sector
1.3.1 Overview of the finance industry
This section will provide a broad overview of the relationship among the various players in the
financial system. Simply a corporation can be viewed as an entity that raises capital and then
puts that capital to work at whatever it is that company specializes in.
11
A corporation finances its activities by issuing equity via initial public offering (IPO) or
secondary offering, issuing debt, and using cash flows from operations. The decisions about how
much capital is required to achieve operational and strategic objectives will determine whether
and in what proportion debt and equity will need to be raised. Companies make these decisions
internally and sometimes will seek advice from investment banks.
1.3.2 Different forms of capital
As alluded to earlier, biopharmaceutical companies can obtain additional capital through
partnerships with larger pharmaceutical companies. There are however other sources of capital
such as venture capital, initial public offerings (IPOs), marketed follow ons, private investments
in public equity (PIPE), registered direct offerings (RDOs) and bank loans.
Venture Capital Equity InvestmentVenture Debt
Equity hivestment
Pnvate Equity Project Financing
Milestone Monetization
IPO
Investment Bank Marketed Follow On
PIPE / RDO
Leveraged Recap Convertible Debt
Phanua In-house VC ains
Corporate Partnership Equity Investment
In-Licensing/Co-Development
Figure 3 Different types of capital sources for biopharmaceutical companies
The composition of capital sources for biopharmaceutical companies tends to vary with the
different stages of the companies' life cycle, which will be discussed in Section 1.3.4. Overall,
venture capital provides a large portion of funding for biopharmaceutical drug developing
companies. Grants and loans are an important financial source in the early stages of drug
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development, while IPOs and other types of public funding are mostly relevant in the later stages
and for product candidates that are close to the market.
The global financial crisis in late 2008 had a wide-reaching impact on the economy as a whole,
including biopharmaceutical companies. Their typical sources of capital adapted their investment
strategies to respond to the new economic realities.
Venture Capital
Venture capital (VC) has always been based on three key elements: deal sourcing, monitoring
and exiting. With a number of notable shifts in the investment landscape, many VC firms are
shifting in what they invest in and their investment structures to increase capital efficiency and
shorter development cycles.
For early stage companies, many VC firms are deploying portions of capital over time at several
milestone-driven "tranches." Such structure seems to align incentives of VCs and those of
companies. VCs can manage total return on investment as they can pull capital from their
investors in a more staged manner and company management is driven to achieve upcoming
milestones and stay focused throughout to deliver results.
With IPOs still being a challenging exit option, VC firms work towards increasing the likelihood
of an exit by acquisition. New investments increase their focus on companies that develop
products targeting diseases that fall within the portfolio strategy of established biopharmaceutical
companies. VC firms therefore work with pharma earlier on in a company's life cycle and even
form a partnership to receive guidance on how to design critical development stage studies
(Licking 2009).
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Private Equity
Non-venture capital private equity (PE) firms typically invest in mid-stage biotech companies
using specific financing structures. There are two major forms of financing.
a. Project Financing
Project financing provides a unique source of non-dilutive capital for mid-stage biotech
companies. Typically, a PE firm purchases the rights to one or more drug candidates in phase I
development from a biotech company, forms a joint venture company around the assets and then
hires the biotech company to conduct the phase II studies with varying degrees of external
assistance such as contract research organizations. Upon successful completion of phase II trials,
the biotech company then has the option to re-acquire the candidates at a pre-determined internal
rate of return (IRR). The rationale behind this structure is that by taking the product to proof of
concept in a quick and cost-efficient manner, the joint venture has now reached a major value
inflection for the biotech company to raise additional capital on the public markets (Longman
2005).
b. Revenue Interest Financing
For companies with highly promising marketed products or drugs in post phase III, revenue
interest financing allows them to raise relatively inexpensive, non-dilutive capital. Requiring
fewer covenants than a traditional debt, such form of financing will also allow more flexibility
for the company. In a typical revenue financing deal, the biotech company will receive an
upfront payment in exchange for a percentage of the future royalty payments or of the future
product revenue for a defined period of time (Levine 2008). If done right, a company could use
a noncore asset to fund a promising product in the pipeline without partnering and independent
of market conditions and potentially realize a greater value from the asset.
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Investment Bank
Healthcare investment banks offer a variety of services to biotech companies including advising
on M&A activity, IPOs, follow-on offerings, PIPEs, RDOs and private placements. An
interesting trend in healthcare investment banking is its shift into the most specialized investment
structures such as revenue interest financing which has been more typical for PE firms.
Corporate Partnership
Established biopharma companies with large amounts of cash yet dried out pipelines have taken
a greater role in the financing of the biotech companies through their own corporate venture
capital (CVC) investment and acquisition activities.
CVC arms have been around since the late 1970s but there has been an increased number of
them including Genentech in 2002, Biogen Idec in 2004 and Boehringer Ingelheim in 2010 to
name a few. There has been an increase in the number of deals done by these groups.
There has been a shift in the deal structure in acquisitions where pharma companies are looking
for creative ways to share risks such as including contingent value rights (CVRs) or structuring
deals based on options. Their structures are largely similar in that they allow risk sharing and
bringing the valuations closer, but they differ in relative emphasis. Under CVR, a large portion
of the purchase price will be paid only upon achieving predefined milestone events. CVRs have
bigger up-front investment compared to option-based deals where the split may be closer to
50/50. In option-based transactions, an established biopharma will pay for the option to acquire a
program or company after a specified milestone. Such structure allows both parties to share the
development risk and bridge potential valuation gaps (Ernst & Young 2011).
In addition to pursuing acquisitions, an established biopharma company forms a strategic
alliance with a biopharmaceutical company. In a strategic alliance, a biopharmaceutical
company, the holder of an intellectual property (IP), partners with a larger pharmaceutical
company for the development and exploitation of the IP.
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Forming an alliance is different from licensing. Licensing typically refers to a passive
relationship where the licensor is not required to do anything else but it passively collects
royalties and other forms of milestone payments that are decided at the time of a license
agreement. Strategic alliances on the other hand, involve more active relationships where both
parties that are involved contribute different yet complementary capabilities. There are many
types of strategic alliances but broadly speaking, there are two major types of alliances in the
biopharmaceutical sector: co-development and co-marketing.
In a co-development alliance, an IP is typically licensed by a biopharma company to its
partnering pharma, and both companies together jointly undertake the further development of a
drug candidate from that IP. Developing a new IP that is based on the licensed IP is the aim of
the collaboration. There are many different ownership structures for this newly developed IP.
Overall, co-development alliance allows the biopharma to add value beyond just granting a
license and therefore be entitled to a larger portion of payments than would otherwise.
In a co-marketing alliance, an IP is similarly licensed by a biopharma to its partner, but in
addition, the partners together access their respective marketing networks and resources to
jointly take the drug product to market (Mendes 2005).
1.3.3 Capital supply and financing gaps
According to a report by Ernst & Young, biotechnology companies across the US, Europe and
Canada raised $ 25 billion in 2010, a number that's comparable to the amounts raised in the
"easy money" years preceding the financial crisis of 2008. Such rebound is definitely
impressive, but a careful analysis reveals that most of this capital belonged to small portion of
the industry. The top 20% of US companies that were most successful in raising funds were
responsible for 82.6% of capital; conversely those in the bottom 20% raised only 0.4% of funds
in 2010.
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The "Other" source of financing shown in Figure 4 includes $3.7 billion and $9.4 billion in 2009
and 2010, respectively, of debt raised by profitable companies in the US. Taking these amounts
out from the sum, "innovation capital" raised by pre-commercial companies actually declined by
21% in 2010 (Ernst & Young 2011).
Wnture 0 IPOs Follow-ons Other
$25
$20
$10
$5
so
2006 2007 2008 2009 2010
IPOs 1,097 697 6 1.238 944 626 1.618 448 456 208 4.997
Ottwr 12.242 7.617 6.832 12.195 10.953 6.788 8,964 8.306 5.242 3.635 9.987
1TW 2,72O =A4 12,9 21,3. 20,313 14,4 14,979 14.405 E,6t& 7,90 32,702
Sourc: Ernst & Young 2011
Figure 4 US yearly biotechnology financing (US $m)
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1.3.4 Life cycle of a biopharmaceutical company
Biotech Start UP Life Cycle
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Figure 5 Lifecycle of biotech start up and its constituencies
Throughout the financial lifecycle of a biopharmaceutical start up, there are many stakeholders
that get involved to help the company to reach the next value creating stage. Figure 5 provides
an overview of different constituencies contributing at various points in the company's financial
lifecycle from the seed stage to its maturity.
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Figure 6 Financial life cycle of biopharmaceutical company
The initial funding or "seed capital" of a growing biotech company is typically made up of a
number of sources such as government or institutional grants, family, friends, and wealthy
individuals ("angel investors"). Such funding is relatively modest, typically less than $5 million.
At this early stage, the founders, often the innovators and co-investors, own 100% of the
company.
As the company successfully moves away from labs and animal studies and towards human
clinical trials, its capital requirement grows significantly. To be able to test a compound in
humans in the US, a number of in vitro and in vivo preclinical tests must be completed and then
an investigational new drug (IND) application must be filed with the FDA. This process typically
costs around $5- 10 million for a single drug. At this juncture, the initial investors have a choice
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whether to maintain their ownership share of the company and invest additional capital. Most of
the time, the large capital requirement for IND-enabling studies goes beyond what typical angel
investors are willing to invest and therefore, the company needs to seek new sources of
financing.
This is where VC comes into a company's lifecycle. As mentioned in the earlier section, VC
firms typically manage pools of money contributed from university endowments, pension funds,
and other large institutions. They then seek promising early-stage companies in which they can
invest. Given that typical venture capitalists prefer three to seven years to realize their returns,
companies with realistic monetizable value inflection points will be able to raise money from VC.
Venture investors typically seek both a dilutive equity stake in the company and significant
control over its operations and strategic direction via controlling through a company's board of
directors. The ownership shares given to new venture capital investors in exchange for their
capital will come from those of the founders. Consequently the founders' shares get diluted and
they will now own smaller portions of the company. Over the course of multiple rounds of new
capital leading to an IPO, the founders' stake will be diluted even further.
Upon filing an IND application and receiving an approval from the FDA, the company can begin
its clinical studies in patients or normal volunteers. Receiving this initial approval is a
transformative step for a small biotech company. The value of the compound is increased, thus
driving up the value of the company. Conversely, the company's need for capital increases
enormously because of the cost of performing human studies. This means that once again the
biotech will need to raise money.
A typical clinical testing goes through three successive phases. In Phase I, a small group of
usually healthy individuals (20-80) are tested to establish safe dosage and identify potential side
effects. Phase II trials are larger (100-300) and are conducted with subjects who have the
targeted disease or condition. They are designed to obtain evidence on safety and preliminary
data on efficacy. The final pre-approval phase, Phase III trial, also known as pivotal trial,
requires a large number of patients (1000-3000) and is designed to confirm the study drug's
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effectiveness, monitor side effects and compare it to commonly used treatments. Once the
company believes that it has enough safety and efficacy data, it will submit either a new drug
application (NDA) or a biological license application (BLA) to the FDA for review and approval
(Clinicaltrials.gov).
At this stage of the company's life cycle, there will be other types of investors that may become
interested in providing capital. Such types of investments are called "crossover funds" and they
tend to invest in both growing private and more mature public companies. In addition,
established pharmaceutical companies with their venture capital arm become interested. These
new rounds of capital to support more advanced clinical development are often known as "Series
D" and "Series E" rounds and so-called "mezzanine capital." These investors have even shorter
investment time horizons typically ranging from a few months to one or two years. The growth
capital that later-stage venture and crossover investors provide is typically used towards
generating additional clinical data to identify the therapeutic value of the drug (Hall and Wood
2008).
Clinical proof of concept is one of the most significant value-inflection points in the cycle of a
drug's development and in order to complete studies to generate meaningful data, it will require a
significant amount capital as discussed in Section 1.2.2. Therefore in order to continue its
trajectory, it is essential for the company to consider innovative forms of financing its drug
development.
It is typically only at maturity that any of the investors including those from seed stage to
crossover fund stage have the opportunity to realize a return on their investment. Since the
biotech business model is based on monetizing IP, a biotech company enters its maturity only
after advancing through multiple value inflection points and reaching the stage where its
investors can realize a gain from their investment. There are several exit options available for
these investors and it depends largely on the appetite of prospective public equity investors
through an IPO and of established pharmaceutical companies for potential acquisition.
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The rest of the thesis is organized as follows. Chapter 2 will discuss the objective and
methodology of the study and Chapter 3 will discuss the results from the data analysis and the
implications of the study findings. Lastly, potential short falls and next steps will be discussed in
Chapter 4 to conclude the thesis.
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2. Thesis objective and methodology
2.1 Objective
We set out to investigate factors that executives at small to mid-sized biopharmaceutical
companies should consider around the time of drug launch, a critical event that can directly
impact a company's valuation.
2.2 Hypotheses
a. Companies that provide their own estimates perform better than those that do not provide
guidance for estimated sales. Providing their own estimates allows the company to set
modest estimates compared to those set by the analysts without the company
management's guidance.
b. Companies that succeed in launching a drug make aggressive business development
decisions and raise additional capital at the "right time." Companies that raise additional
capital before drug launch perform better than those that do so after the launch.
c. A partnership with a larger company contributes to a successful drug launch.
d. Drugs for specialty markets or with an orphan indication perform better than those for
primary care markets.
2.3 Methodology
2.3.1 Data collection
A list of new molecular entities (NMEs) and biologics license applications (BLAs) that were
approved by the FDA from January 1, 2000 - December 31, 2009 was compiled from the FDA
website. A total of 253 products were identified (Appendix A). A list of companies that owned
the product at the time of approval was also compiled.
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To be included in this analysis, companies that launched the drug had to meet two requirements:
" The firm had to be listed on some US. Exchange at the time of drug approval
e Its market capitalization had to be less than $ 20B at the time of approval
Fifty-one drugs met these initial criteria. We then identified the US. launch date for these
selected drugs using EvaluatePharma and company press releases.
We classified drugs as specialty pharmaceuticals or primary care products by reviewing
company press-releases for a specific designation and interviewing a physician to determine
whether specialists or PCPs were the primary prescribers. We excluded 5 drugs that were non-
therapeutic such as diagnostics or imaging agents.
Ultimately, the database for analysis included 46 drugs. The full list of drugs included in our
study is provided in Appendix B.
We then collected data on several key variables we hypothesized to have correlation with change
in stock price and/or market capitalization. To test Hypothesis (a), management sale guidance
data was compiled by reviewing business updates and earnings conference call transcripts within
one year before and after the launch date (Appendix C); Thomson ONE research database was
used to access the reports. Historical analyst sales estimates were obtained from EvaluatePharma.
Estimates that were made within one year before and one year after the launch were collected on
a quarterly basis. At each date, I captured sales estimates for the launch year (Y=O) and that of
years 1, 2 and 3 after the launch. The companies' actual sales data for the first two years after
the launch date was also collected from EvaluatePharma database.
For Hypothesis (b), Capital IQ was used to capture public follow-on financing activities within a
period of two years before and two years after the launch. The type of security and both file and
offering dates were captured to calculate file-to-offer discounts.
Partnership information was collected from commercial databases including EvaluatePharma and
Capital IQ to test Hypothesis (c). If there was a partnership at launch, the type of partnership
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(e.g. co-promotion and/or co-development) was also captured. Company press releases were
also used to cross check the information. Market related data including share price and market
capitalization of the partnering company was obtained from Capital IQ and FactSet.
Lastly for hypothesis (d), primary drug indication was collected from EvaluatePharma. Company
press releases were used to identify whether specialists or PCPs were the primary prescribers.
The findings were confirmed with a primary care physician from Massachusetts General
Hospital.
2.3.2 Data analysis
We benchmarked the performance of these companies across both stock price and market
capitalization with the performance of the Nasdaq Biotechnology Index (NBI). We used market
capitalization, in addition to stock price, to be sure we captured the impact of company stock
issuances. To isolate the performance of each company from the background performance of the
market, each company's change in stock price or market capitalization was adjusted for the
underlying performance of the NBI during the relevant time period.
Because the launch of a product typically triggered a fluctuation of a company's market
capitalization, we normalized company stock price and market capitalization to themselves at six
months prior to drug launch. Since we adjusted each company's individual performance to the
performance of the market, we were able to directly compare the performance of all companies
between January 2000 and December 2009. We were also able to compare large and small
companies, because we measured performance as a percent of stock price and market
capitalization.
2.3.3 Regression modeling
Predictor variables that were initially considered in the analysis are the following: guidance
(binary), partnership (binary), market size of the partner(s) at the time of launch,
specialty/primary care indication (binary), difference between year two actual sales number and
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that of pre-launch estimate, difference between year two actual sales number and that of post-
launch estimate, financing activity prior to launch (binary), financing activity after launch
(binary), average pre-launch file-to-offer discount, average post-launch file-to-offer discount,
number of drugs launched by the same company (control variable) and NBI performance
(control variable).
We then performed multiple linear regression analyses to determine which of these parameters
were predictive of change in market value using the software package JMP9.
It is worth reemphasizing that the purpose of our model is to understand which variable is
significant and how it will impact the average financial performance of the companies, not to
make a precise prediction of the financial performance of the individual companies. A number
of different combinations of variables were used to construct various models. Given the
unavoidable multicollinearity, several combinations of variables are used to generate outputs
from various models. It is possible to detect the sensitivity of a variable, i.e. how easily the
parameter estimate changes upon adding or removing other variables. Therefore, the more
sensitive the variable is, the more dependent it is on other variables in the model. Therefore such
a variable is not informative as it provides inconsistent interpretation. Conversely, a variable that
consistently demonstrates a significant relationship with minimal fluctuation in its impact on the
overall model would be an informative variable; it could be used as an additional tool to aid the
management when considering various factors during the time around a drug launch.
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3. Results
3.1 Model 1: percentage change of stock price
Through multiple iterations, our analysis identified that three of the previously stated variables
from Section 2.3.3 explain the change in stock price of the company: management guidance,
actual sales beating analysts' estimates made post-launch date (actual sales at Year 2 since
launch > analyst estimates made post-launch) and post-launch financing.
The primary driver is whether or not the management provides guidance. Guidance contributes
significantly throughout different models, confirming our proposition that it is a solidly unique
contributor to the change in share price. Giving guidance accounts for a 75% decline (estimate
of 0.25) in share price from six months before the event to two years after the drug launch. Its
impact in the model is very significant.
Secondly, beating analysts' sales estimates that were made post-launch also was consistently
significant among different models. Drugs that beat analyst estimates made post-launch
contributed to a 6% increase in stock price from six-months prior to the drug launch to two years
after the launch.
Lastly, timing of financing was identified as another informative variable. Stocks of companies
that raised additional capital after the drug launch performed better by 24% than those that
pursued financing before the launch or did not pursue financing at all.
In addition to understanding which factors played a role in driving the performance of share
price, it is equally important to understand the factors that were not significant. Having a
partnership at launch does not contribute significantly to percent change in share price. That
outcome might be indicating that managing expectations at the time of launch is more relevant.
In addition, being a specialty/orphan drug does not correlate with change in share price. Its
impact gets completely washed out (estimates close to zero) when other variables change in the
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model. Having a partnership or being a specialty drug perhaps inherently bestows greater merits
on the product but does not contribute to share performance.
3.2 Model 2: percentage change of market capitalization
Through multiple iterations, our analysis identified that two of the previously stated variables
from Section 2.3.3 explain the change in market capitalization of the company: management
guidance and post-launch financing.
Similar to what was observed in the share price performance analyses, whether or not the
management provides guidance was the primary driver. Guidance contributes significantly
throughout different models, confirming our belief that it is a solidly unique contributor to the
change in market capitalization. Giving guidance accounts for a 45% decline in the market
capitalization from six months before to two years after the drug launch.
Timing of financing was also consistently significant throughout the analyses. The companies
that raised additional capital after the drug launch experienced a 28% larger change in the market
capitalization than those that raised capital before the launch or did not pursue financing at all.
Variables that were not significant in the model can equally be informative and are worth the
effort to understand the potential implications of the findings. Neither having a partnership nor
being a specialty drug contributes significantly to changes in market capitalization of the
company around the time of a drug launch.
28
4. Discussion
Hypothesis (a) was based on an assumption that managements who offer guidance are more
conservative in projecting their future sales in the hopes of guiding the Street to publish more
tangible sales goals for the company. The results from our study suggest otherwise. Two years
after the drug launch, shares of companies that provided guidance around the time of a drug
launch were down from the prices at six months before the launch. A similar relationship was
observed when the model looked at the changes in the market capitalization. A potential
interpretation of the result could be that those companies that provide guidance may have greater
confidence in the performance of the drug in the market and unintentionally portray a rosier
future. Setting the expectation higher may have led the market to be disappointed with the actual
performance of the drug in the market, which consequently punished the company's stock.
The regression outcome for the impact of analyst estimates and actual sales data was not
surprising. One would rightly expect that analyst estimates will get refined as time progresses
and the uncertainty associated with launch decreases. Based on this reasoning, it is reasonable
that the investment community puts greater emphasis on how the company performs against the
analysts' estimates made on a later date.
With such a high degree of uncertainty associated with drug launches, shorting against the
launch now has become a widespread investment strategy. With this pattern in the industry,
hypothesis (b) was based on an assumption that the public would be generally disappointed with
the drug's performance after the launch. Therefore raising additional capital post-drug launch
would be less favorable to the company's financial performance compared to pursuing additional
financing before the launch. Interestingly enough, the timing of financing was significant
amongst various models, yet the outcome was contrary to our expectation. Companies that
pursued additional rounds of financing after the drug launch performed better both from the
stock price performance perspective and that of the market capitalization. There are many
possible explanations for this observation. One might be that companies with more positive
outlooks on their drug performance may have pursued additional rounds of financing and indeed
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were able to secure more funding to conduct post-commercialization activities that led to a
successful performance.
Another potential interpretation of this observation may come from a mechanical aspect of
financing in general. If a company pursues an additional round of financing before the launch,
the impact of an earlier dilution might be greater and might linger for a longer period of time.
Such a dilution effect could be reflected in the stock performance of those companies that raised
additional financing before the drug launch.
Neither a partnership nor the market size of the partner contributed to either of the outcome
measures. Whether or not the product is a specialty product also did not make any significant
contribution to the models. These findings were particularly striking. Hypothesis (c) assumed
that having a partner, especially if the partner was larger than the company launching the drug,
might contribute to the success of a drug launch due to the partnering company's resources.
With the recent commercial success of specialty pharmaceuticals as described by Gudiksen et al.
(2008), our hypothesis (d) was set out to test whether a specialty drug's novel concept would
translate to a better performance of the stock. Our finding does not necessarily contradict the
findings of previous studies, but rather suggests that the performance of stock and/or market
capitalization is largely driven by managing the expectation of the investors rather than more
intrinsic attributes of the product. The market may have already priced in good performance of
those drugs and did not reward their performance, as it was already expected
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5. Conclusion
This study was not designed to provide a prescriptive answer to what will lead to a successful
drug launch. The findings from this study, however, will provide several valuable advising tools
for management during the period around a drug launch. Bringing a product to market is a
critical event for any biopharmaceutical company. It marks a major turning point within the
biopharmaceutical's lifecycle and the company that can successfully launch a product will be
viewed as a different asset class, one that has a lower risk profile. Therefore, it is critical to
understand potential drivers of the value and to encourage executives to raise provocative
questions when they are pursuing the next round of financing or whether to provide guidance.
This study suggests that there are several possible strategic and actionable considerations that
can guide management to ask the right questions. Asking the right questions will help
management make better decisions that will eventually translate to a better stock performance
and possibly a growth in market capitalization in the course of a drug launch. We found that
those companies that did not provide guidance at the time of launch and raised additional capital
within two years after launch performed better than that did otherwise. There are many other
strategic principles, such as building a sustainable pipeline, which a company should consider to
become an enduring player in this rapidly changing industry.
There are several limitations to the study. Firstly, this study was based on a small sample size.
Nonetheless, ascertainment of a larger study data set is unachievable in that there are only a
certain number of drugs produced by small- to mid-cap companies that receive FDA approval. In
addition, some of the historical data, such as analyst estimates of sales or management's sales
guidance, are inherently challenging to retrieve. Given that the sample of 46 was small and that
this research was not a designed study, we did not use R-square value. We believe, however, that
for our study purposes, the small sample size does not pose major problems for our analysis
because this study was not intended to provide quantitative prediction but to provide a list of
factors that management would do well to consider during the period around a drug launch.
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Drug Name
IPLEX
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ISTA PHAIRMS
UNITED THERAP
TERCICA
PROGENICS
DYAXCORP.
CUBIST
BIOMARIN
ALLOS
KEDICINES CO
SALIX PHARMS
SCIOS
THERAVANCE INC
KEDICINES CO
ALEXMON PHARM
REGENERON PHARMACEUTICALS
AMYLIN
CELL THERAPEUTICS
AMYLIN
IMCLONE
WATSON LABS
BIOMARIN PHARM
OSI PHARMS
MLLENNIUM PHARMS
CEPHALON
PHARMION
WATSON LABS
SUNOVION PHARMS INC
(FORKER SUPRACOR, SEPR)
GILEAD
GILEAD
ALLERGAN
CELGENE
ALLERGAN
GILEAD
FOREST LABS
GENZYE
GENZYNE
GENZYNE
FOREST LABS
FOREST LABS
BIOGEN IDEC
SALIX PHARMS
ILEX PHARMACEUTICALS
Date of Approval rket Capitai2aon at D Lbrket Capitalizaion at Speciaty(1) wApprol ($ millions) Launch ($ millions) Primarycare (0)
Appendix B List of drugs and companies analyzed
(Sources: FDA website, EvaluatePharma, Capital IQ, Thomson One research reports, company press-releases and
interviews with a physician)
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Appendix C Selected Commentary for Management Guidance
- "Baxter expects sales of HYLENEX, including co-formulations as well as kitted products,
could potentially reach $500 million." -Baxter International Investor Day, Brean Murray
Carret & Co. Analyst Report 3/15/07
" "We expect 2008 net sales of Kuvan to be in the range of $35 million to $70 million. This
wide range is attributable to the many uncertainties with first year product launches and
also variables that take into consideration the average patient weight and dose, the
logistics of getting patients tested in the clinics and patient compliance." -Biomarine
Pharmaceutical conference call 12/13/07
" "We deferred revenue on these orders in the third quarter as Cleviprex is a new product
and we do not have enough history to estimate our gross to net adjustments or sales
patterns. However, we reiterate our full-year 2008 guidance for Cleviprex of $5 million
to $10 million. "- Medicines Company conference call 10/22/08
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Appendix D Regression output and control variables
(Sources: FDA website, EvaluatePharma, Capital IQ, Thomson One research reports, company press-releases and
interviews with a physician)
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Relative Share Price Performance
Since Six Month Pre- to Two Years Post-Launch
Rapaflo Share Price
330 - - -
230
130 -
-130
-230 
---
d
Rapaflo -NBI (Indexed)
Appendix F Relative share price performance: Rapaflo
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30
Relative Share Price Performance
Since Six Month Pre- to Two Years Post-Launch
Cleviprex Share Price
170
120 -
70
20
-30
-80 - -
Cleviprex- NBI (Indexed)
Appendix G Relative share price performance: Cleviprex
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Relative Share Price Performance
Since Six Month Pre- to Two Years Post-Launch
Bystolic Share Price
150
100
50
0
-50
-soN
Bystolic NBI (Indexed)
Appendix H Relative share price performance: Bystolic
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Relative Share Price Performance
Since Six Month Pre- to Two Years Post-Launch
Tysabri Share Price
160
110 -
60
10
-40 -
Tysabri NBI (Indexed)
Appendix I Relative share price performance: Tysabri
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